Pancreaze (Pancrelipase) Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Pancreaze (pancrelipase) is a prescription medication that combines digestive enzymes, including amylase, lipase, and protease, to help the body digest food. It is primarily prescribed to individuals with pancreatic insufficiency, which can be caused by conditions such as cystic fibrosis or chronic pancreatitis.

The main forms of Pancreaze (pancrelipase) are capsules and tablets. The capsule form is designed to be swallowed whole and contains a powder or granules inside a soft or hard shell that dissolves in the stomach, releasing the active enzymes. Pancreaze is used across various age groups, including children, adults, and geriatrics. It is distributed through several channels such as hospital pharmacies, retail pharmacies, and online pharmacies. The medication is typically used to manage conditions like chronic pancreatitis, cystic fibrosis, and other related applications.

Tariffs are influencing the pancreaze market by increasing costs associated with imported active enzyme ingredients, pharmaceutical-grade excipients, capsule manufacturing materials, and specialized processing equipment. These impacts are most evident in North America and Europe, where enzyme-based drug production depends on global sourcing networks. Higher tariffs can increase production costs and affect pricing strategies for chronic therapies. However, they are also encouraging domestic enzyme production, regional sourcing of raw materials, and investments in localized pharmaceutical manufacturing capacity to strengthen supply reliability.

The pancreaze (pancrelipase) market research report is one of a series of new reports from The Business Research Company that provides pancreaze (pancrelipase) market statistics, including pancreaze (pancrelipase) industry global market size, regional shares, competitors with a pancreaze (pancrelipase) market share, detailed pancreaze (pancrelipase) market segments, market trends and opportunities, and any further data you may need to thrive in the pancreaze (pancrelipase) industry. This pancreaze (pancrelipase) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pancreaze (pancrelipase) market size has grown strongly in recent years. It will grow from $1660.16 million in 2025 to $1756.2 million in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increasing incidence of pancreatic insufficiency, rising prevalence of cystic fibrosis, limited natural enzyme production therapies, advancements in pharmaceutical enzyme formulation, expansion of gastroenterology care services.

The pancreaze (pancrelipase) market size is expected to see strong growth in the next few years. It will grow to $2173.57 million in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to expansion of long-term digestive disease management, increasing adoption of personalized enzyme dosing, growing elderly population with digestive disorders, rising awareness of pancreatic enzyme therapies, improvements in oral drug delivery technologies. Major trends in the forecast period include increasing demand for enzyme replacement therapies, rising focus on digestive disorder management, expansion of personalized dosage formulations, growing use of chronic enzyme supplementation, enhanced stability of oral enzyme products.

The rising incidence of cystic fibrosis is expected to drive the growth of the Pancreaze (pancrelipase) market in the coming years. Cystic fibrosis is a genetic disorder that impacts the lungs, digestive system, and other organs by causing the production of thick, sticky mucus. This leads to blockages, infections, and impaired organ function. The increase in cystic fibrosis cases is largely attributed to improved awareness, better diagnostic techniques, and expanded genetic screening programs that help identify more cases, including milder forms that may have previously gone undiagnosed. Pancreaze (pancrelipase) is used in the treatment of cystic fibrosis to assist digestion by replacing the enzymes that the pancreas cannot produce effectively. This helps patients absorb nutrients from food, improving their overall nutritional health. For example, in October 2024, the Cystic Fibrosis Trust, a UK-based charity, reported that in 2022, 11,148 cystic fibrosis patients were registered, with the number rising to 11,318 in 2023, reflecting a 1.5% increase in patient registrations year-over-year. As a result, the growing prevalence of cystic fibrosis is driving the growth of the Pancreaze (pancrelipase) market.

The increasing incidence of pancreatic conditions is expected to further drive the growth of the Pancreaze (pancrelipase) market. Pancreatic conditions, which include disorders such as pancreatitis, exocrine pancreatic insufficiency (EPI), pancreatic cancer, and diabetes, impair the pancreas' digestive and hormonal functions. The incidence of these conditions is on the rise due to factors such as obesity, diabetes, alcohol overuse, smoking-related complications, and improved diagnostic tools that enable earlier detection. Pancreaze helps manage these conditions by restoring digestive enzyme levels, improving nutrient absorption, and alleviating symptoms like malnutrition and diarrhea. For instance, in February 2023, Cancer Research UK, an independent cancer research organization, reported that the annual number of new pancreatic cancer cases in the UK is expected to rise from approximately 12,500 cases in 2023-2025 to around 16,000 cases by 2038-2040. This represents a 5% growth in incidence rates, reaching an average of 19 cases per 100,000 people annually by 2038-2040. Therefore, the increasing incidence of pancreatic conditions will drive the growth of the Pancreaze (pancrelipase) market.

A key trend in the Pancreaze (pancrelipase) market is the increasing emphasis on clinical evidence to support the drug's efficacy, particularly through clinical trial data. This data plays a crucial role in enhancing regulatory approval processes, improving patient outcomes, and strengthening a drug's competitive positioning. For example, in May 2024, Vivus, Inc., a US-based biopharmaceutical company, announced the publication of new clinical trial data highlighting the efficacy of PANCREAZE (pancrelipase) in stabilizing weight among chemotherapy patients with pancreatic ductal adenocarcinoma (PDAC) who were also suffering from cachexia and exocrine pancreatic insufficiency (EPI). The findings also suggested potential benefits of PANCREAZE in reducing stool frequency and improving stool consistency. This study was conducted as an investigator-initiated trial by researchers at Cedars-Sinai Medical Center and the Samuel Oschin Cancer Center.

Major companies operating in the pancreaze (pancrelipase) market are AbbVie Inc.

North America was the largest region in the pancreaze (pancrelipase) market in 2025. The regions covered in the pancreaze (pancrelipase) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pancreaze (pancrelipase) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The pancreaze (pancrelipase) market consists of sales of pancreaze delayed-release capsules, pancreaze powder, and pancreaze oral pellets. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pancreaze (Pancrelipase) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses pancreaze (pancrelipase) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pancreaze (pancrelipase) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pancreaze (pancrelipase) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Capsule; Tablet
• 2) By Age: Children; Adults; Geriatric
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Application: Chronic Pancreatitis; Cystic Fibrosis; Other Applications
• Companies Mentioned: AbbVie Inc.
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.